BIO Study On Follow-On Biologics Focuses On Trade-Off Between Savings And R&D
This article was originally published in The Pink Sheet Daily
Executive Summary
Study extrapolates from CBO’s scoring of last year’s Senate bill to argue that “shorter exclusivity could lead to the worst of both worlds – fewer new biologics … and little savings.”